Download Mendeley7-(Pyrazol-4-Yl)-3H-Imidazo[4,5-B]Pyridine-Based Derivatives for Kinase Inhibition: Co-Crystallisation Studies with Aurora-A Reveal Distinct Differences in the Orientation of the Pyrazole N1-Substituent.
Bavetsias, V., Perez-Fuertes, Y., Mcintyre, P.J., Atrash, B., Kosmopoulou, M., O'Fee, L., Burke, R., Sun, C., Faisal, A., Bush, K., Avery, S., Henley, A., Raynaud, F.I., Linardopoulos, S., Bayliss, R., Blagg, J.(2015) Bioorg Med Chem Lett 25: 4203
- PubMed: 26296477
- DOI: https://doi.org/10.1016/j.bmcl.2015.08.003
- Primary Citation of Related Structures:
5AAD, 5AAE, 5AAF, 5AAG - PubMed Abstract:
Introduction of a 1-benzyl-1H-pyrazol-4-yl moiety at C7 of the imidazo[4,5-b]pyridine scaffold provided 7a which inhibited a range of kinases including Aurora-A. Modification of the benzyl group in 7a, and subsequent co-crystallisation of the resulting analogues with Aurora-A indicated distinct differences in binding mode dependent upon the pyrazole N-substituent. Compounds 7a and 14d interact with the P-loop whereas 14a and 14b engage with Thr217 in the post-hinge region. These crystallographic insights provide options for the design of compounds interacting with the DFG motif or with Thr217.
Organizational Affiliation:
Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research, London, United Kingdom. Electronic address: vassilios.bavetsias@icr.ac.uk.
